Precigen Q1: PAPZIMEOS nets $21.6M revenue; loss narrows to $7.9M

PRECIGEN, INC.

2026-Q1 EPS reported -$0.02 vs consensus -$0.03 ▲ beat (+38.7%)

Net product revenue from PAPZIMEOS was $21.6M in Q1 2026, first full quarter post-FDA approval.
Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025.
Patient hub enrollment reached ~400 patients; 25% from community settings.
Cash, equivalents, and investments totaled $56.7M as of March 31, 2026.
Permanent J-code (J3404) assigned effective April 1, 2026, expected to streamline access.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.